Piramal Pharma Solutions invests $74.6 million in ADC and API facilities in the UK

Together, the expansions and upgrades represent a £55 million ($74.6 million) investment in UK drug development and manufacturing capabilities, as well as new employment opportunities for technical and operational staff.

Expansion of the ADC of the Grangemouth site

In the first phase of the expansion of the Grangemouth site, two new ADC manufacturing suites will be added to the three existing sites.

This will more than double Piramal’s ADC production capabilities, with the company noting increased demand for commercial ADCs, coupled with a strong pipeline of clinical materials.

The site is specifically geared towards the development and manufacturing of ADCs and serves the global market with an emphasis on the development of treatments targeting cancer/oncology.

The new build has been designed to accommodate further expansion, with future phases planned that include a new sterile fill/finish suite dedicated to ADCs and two additional large-scale manufacturing suites capable of handling increased batch sizes . A new Customer Experience Center will also help customers who visit the site during development or manufacturing.

Piramal Pharma Solutions considers itself a leader in the development and manufacturing of ADCs, with hundreds of payloads developed and over a thousand batches of ADCs manufactured. When completed, the expansion will significantly improve PPS’ position by increasing ADC capacity at the Grangemouth site. The new facility will be fully supported by analytical laboratories (Quality Control, Cellular Assay and Enzyme Immunosorbent Assay [ELISA]Good Manufacturing Practices [GMP]), warehouses and administrative offices, all housed in a purpose-built facility.

PPS’s Grangemouth facility has two important ADC capabilities: fit-for-purpose rapid development for early clinical materials and robust, scalable late-stage development to support pivotal trials and commercial launch.

“By combining these skills with the offerings of our 13 other global facilities, including fill/finish, payloads and peptides, we can provide integrated ADC services to customers looking for quick and simplified solutions,” says the company.

The £45m Grangemouth expansion is supported by a £2.4m grant from Scottish Enterprise and is also co-funded by the client.

The new facility is being built on a 5 acre brownfield site less than 100 meters from the existing site. This expansion is expected to create around 40-50 new jobs, bringing the total number of employees at the site to over 250 and building on a four-fold increase in recent years.

The official inauguration ceremony took place this week; sites to be operational by Q3 2023.

Investment in the Morpeth site API

The API capacity investment at the Morpeth site, which is valued at around £10 million ($13.6 million), includes new equipment, infrastructure and utility systems.

In addition to meeting growing market demand from global API customers, the investment will help improve the company’s carbon footprint by replacing obsolete equipment with new energy-efficient alternatives. The company is committed to promoting its sites in North America and India in the same way.

PPS is investing £8 million directly, while the UK government is contributing £2 million to the project.

More than 400 people are employed at Morpeth, including approximately 160 directly in API operations.

drug discovery

Last week, CDMO announced that it had also invested several million dollars in a screening facility that will augment existing in vitro biology capabilities at its drug discovery services site in Ahmedabad, India.

This new expansion, which is expected to be commissioned in the third quarter of 2022, will significantly increase the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.

New high-throughput screening technology can evaluate and screen 1,000 compounds per week using various analytical platform technologies such as Fluorescent Imaging Plate Reader (FLIPR), TR-FRET/HTRF , fluorescence polarization (FP), absorbance, luminescence/electrochemiluminescence (ECL), Alpha Screen, Lantha Screen, flow cytometry and high content imaging. These platforms will be applicable to a variety of targets (e.g., G protein-coupled receptors (GPCRs) and targeted kinase therapies).

About Joan Dow

Check Also

Baker McKenzie advises Pacoma on the sale to Legget & Platt | Writing

Baker McKenzie advised Pacoma Holding S.à rl in connection with the sale of the Pacoma …